> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Review Voucher Issued to PTC Therapeutics
- URL: https://www.fdaweb.com/review-voucher-issued-to-ptc-therapeutics/
- Published: 2024-12-03T12:00:00.000Z
- Updated: 2026-09-14T14:48:23.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5158291

*Federal Register* notice: FDA is announcing that a priority review voucher was issued to PTC Therapeutics for its qualified rare pediatric disease product Kebilidi (eladocagene exuparvovec-tneq), which was approved 11/13 for treating adult and pediatric patients with aromatic L-amino acid decarboxylase deficiency. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2024-12-02/pdf/2024-28206.pdf?ref=fdaweb.com).